Dynamic assessment of the filtration function of the kidneys and indicators of muscle mass in patients with sarcopenia and chronic heart failure

Currently, due to the increase in life expectancy in the human population, the relevance of the problem of sarcopenia and chronic somatic pathology, including chronic heart failure (CHF), is increasing. At the same time, there are no clear recommendations for managing patients with a combination of CHF and sarcopenia. In addition, the impact of sarcopenia in combination with CHF on kidney filtration function remains poorly understood. The aim of the study was to evaluate the dynamics of muscle mass and strength, kidney filtration function in patients with sarcopenia and CHF in a longitudinal study involving 53 male patients with a mean age of 75.2 ± 7.3 years. The first (main) group (n = 24) consisted of patients with CHF and sarcopenia, while the second comparison group (n = 29) included patients with CHF without sarcopenia. The results showed that patients in the main group had a more pronounced decrease in muscle mass and strength over time, glomerular filtration rate (GFR), calculated using CKD-EPI formulas, based on cystatin C (CKD-EPI_CysC) and cystatin-creatinine (CKD-EPI_CysC+Cr) levels. In the comparison group, a more significant decrease in GFR, calculated using creatinine, was observed. It is emphasized that for more accurate determination of GFR in patients with CHF and accompanying sarcopenia, it is advisable to use the CKD-EPI_CysC formula. Future controlled randomized studies will determine the possibility of including this recommendation in appropriate protocols for managing elderly patients.

1. Dhillon R.J., Hasni S. Pathogenesis and management of sarcopenia. Clin. Geriatr. Med. 2017;33(1):17-26. DOI: 10.1016/j.cger.2016.08.002

2. Rosenberg I.H. Sarcopenia: origins and clinical relevance. J. Nutr. 1997;127(5):990S-991S. DOI: 10.1093/jn/127.5.990S

3. Cao L., Morley J.E. Sarcopenia is recognized as an independent condition by an international classification of disease, tenth revision, clinical modification (ICD-10-CM) Code. J. Am. Med. Dir. Assoc. 2016;17(8):675-7. DOI: 10.1016/j.jamda.2016.06.001

4. Morley J.E., Anker S.D., Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology update 2014. J. Cachexia Sarcopenia Muscle. 2014;5(4):253-259. DOI: 10.1007/s13539-014-0161-y

5. Zhang Y., Zhang J., Ni W., Yuan X., Zhang H., Li P., Xu J., Zhao Z. Sarcopenia in heart failure: a systematic review and meta-analysis. ESC Heart Fail. 2021;8(2):1007-1017. DOI: 10.1002/ehf2.13255

6. Guljaev N.I., Ahmetshin I.M., Gordienko A.V., Anohin D.Ju., Sajfullin R.F. Sarcopenia in the clinic of internal diseases. Voenno-medicinskij zhurnal. 2018;339(12):24-30. (In Russian). DOI: 10.17816/RMMJ73123

7. Guljaev N.I., Ahmetshin I.M., Gordienko A.V., Jakovlev V.V. Sarcopenia as a cause of underdiagnosis of chronic kidney disease in patients with chronic heart failure. Uspehi gerontologii. 2020;33(1):121-126. (In Russian). DOI: 10.34922/AE.2020.33.1.016. - EDN JXAAYJ

8. Guljaev N.I., Adamov A.A., Oleksjuk A.V., Oleksjuk I.B., Ahmetshin I.M., Pro-horchik A.A., Baksheev V.I. Features of the pathogenesis of sarcopenia and its influence on the prognosis in chronic heart failure in elderly and senile patients. Klinicheskaja gerontologija. 2022;28(7-8):61-73. (In Russian). DOI: 10.26347/1607-2499202207-08061-073

9. Levey A.S., Stevens L.A., Schmid C.H. Zhang Y.L., Castro A.J., Feldman H.I., Kusek J.W., Eggers P., Lente F., Greene T., Coresh J.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009;150(9):604-12. DOI: 10.7326/0003-4819-150-9-20090505000006

10. Studenski S.A., Peters K.W., Alley D.E., Cawthon P.M., McLean R.R., Harris T.B. Ferrucci L., Guralnik J.M., Fragala M.S., Kenny A.M., Kiel D.P., Kritchevsky S.B., Shardell M.D., Dam T.L., Vassilieva M.T.; The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J. Gerontol. A Biol. Sci. Med. Sci. 2014;69(5):547-58. DOI: 10.1093/gerona/glu010

11. Grinin V.M., Shestemirova Je.I. Demographic aging in Russia at the present stage. Vestnik RAMN. 2015;70(3):348-354. (In Russian). DOI: 10.15690/vramn.v70i3.1332

12. Inouye S.K., Studenski S., Tinetti M.E., Kuchel G.A. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J. Am. Geriatr. Soc. 2007;55(5):780-91. DOI: 10.1111/j.1532-5415.2007.01156.x

13. McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Bohm M., Burri H., Buttler J., Celutkiene J. Chioncel O., Cleland J.G., Coats A.J., Crespo-Leiro M.G., Farmakis D., Gilard M., Heymans S. et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021;42(36):3599-3726. DOI: 10.1093/eurheartj/ehab368

14. Zarudskij A.A. Sarcopenia and its components in patients with systolic chronic heart failure. Sovremennye problemy zdravoohranenija i medicinskoj statistiki. 2020;2:132-143. (In Russian). DOI: 10.24411/2312-2935-2020-00037

15. Chronic Kidney Disease Prognosis Consortium; Matsushita K., van der Velde M., Astor B.C., Woodward M., Levey A.S., de Jong P.E., Coresh J., Gansevoort R.T. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative metaanalysis. Lancet. 2010;375(9731):2073-81. DOI: 10.1016/S0140-6736(10)60674-5

16. Targher G., Zoppini G., Chonchol M., Negri C., Stoico V., Perrone F., Muggeo M., Bonora E. Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals. Nutr. Metab. Cardiovasc. Dis. 2011;21(4):294-301. DOI: 10.1016/j.numecd.2009.10.002

17. Waas T., Schulz A., Lotz J., Rossmann H., Pfeiffer N., Beutel M.E., Schmidtmann I., Münzel T., Wild P.S., Lackner K.J. Distribution of estimated glomerular filtration rate and determinants of its age dependent loss in a German population-based study. Sci. Rep. 2021;11(1):10165. DOI: 10.1038/s41598-021-89442-7

18. Chronic kidney disease (CKD). Clinical recommendations. (In Russian). [Electronic resource]. URL: https://rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf

19. Shlipak M.G., Matsushita K., Ärnlöv J., Inker L.A., Katz R., Polkinghorne K.R., Rothenbacher D., Sarnak M.J., Astor B.C., Coresh J., Levey A.S., Gansevoort R.T.; CKD Prognosis Consortium. Cystatin C versus creatinine in determining risk based on kidney function. N. Engl. J. Med. 2013;369(10):932-43. DOI: 10.1056/NEJMoa1214234

20. Canales M.T., Blackwell T., Ishani A., Taylor B.C., Hart A., Barrett-Connor E., Lewis C., Beyth R.J., Stone K., Ensurd K. E.; Outcomes of Sleep Disorders in Older Men (MrOS Sleep) Study. Estimated GFR and Mortality in Older Men: Are All eGFR Formulae Equal. Am. J. Nephrol. 2016;43(5):325-33. DOI: 10.1159/000445757. PMID: 27166079

21. Cheang I., Liao S., Yao W., Lu X., Gao R., Zhou Y., Zhang H., Li X. Cystatin C-based CKD-EPI estimated glomerular filtration rate equations as a better strategy for mortality stratification in acute heart failure: A STROBE-compliant prospective observational study. Medicine (Baltimore). 2020;99(44):e22996. DOI: 10.1097/MD.0000000000022996

22. Löfberg H., Grubb A.O. Quantitation of gamma-trace in human biological fluids: indications for production in the central nervous system. Scand. J. Clin. Lab. Invest. 1979;39(7):619-26. DOI: 10.3109/00365517909108866

23. Grubb A., Simonsen O., Sturfelt G., Truedsson L., Thysell H. Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med. Scand. 1985;218(5):499-503. DOI: 10.1111/j.0954-6820.1985.tb08880.x

24. Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin. Nephrol. 1992;38(1):S20-7.

25. Chen D.C., Potok O.A., Rifkin D., Estrella M.M. Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR. Kidney360. 2022;3(10):1807-1814. DOI: 10.34067/KID.0003202022

26. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl. 2013;3(1):1-150. [Electronic resource]. URL: https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf

27. Senile asthenia. Clinical recommendations. Ministry of Health of the Russian Federation. 2020. (In Russian). [Electronic resource]. URL: https://rgnkc.ru/images/metod_materials/KR_SA.pdf

28. Falls in elderly and senile patients. Clinical recommendations of the Ministry of Health of the Russian Federation. 2020. (In Russian). [Electronic resource]. URL: https://rgnkc.ru/images/metod_materials/KR_Padeniya.pdf

29. Order of the Ministry of Health of the Russian Federation No. 272n dated 04/20/2022 “On approval of the standard of medical care for adults with chronic heart failure (diagnosis, treatment and follow-up)”. (In Russian). [Electronic resource]. URL: https://rg.ru/documents/2022/06/03/minzdrav-prikaz272-site-dok.html

30. Mareev V.Ju., Fomin I.V., Ageev F.T., Begrambekova Ju.L., Vasjuk Ju.A., Garga-neva A.A, Gendlin G.E., Glezer M.G., Got'e S.V., Dovzhnko T.V. et al. Qinical guidelines OSSN - RKO - RNMOT. Heart failure: chronic (CHF) and acute decompensated (ADHF). diagnosis, prevention and treatment. Kardiologija. 2018;58(6S):8-158. (In Russian). DOI: 10.18087/cardio.2475

31. Grubb A. Cystatin C is Indispensable for Evaluation of Kidney Disease. EJIFCC. 2017;28(4):268-276

32. Zhu C., Zhang H., Shen Z., Chen J., Gu Y., Lv S., Li Y., Zhu B., Ding X., Zhang X. Cystatin C-based estimated GFR performs best in identifying individuals with poorer survival in an unselected Chinese population: results from the China Health and Retirement Longitudinal Study (CHARLS). Clin. Kidney J. 2022;15(7):1322-1332. DOI: 10.1093/ckj/sfac070